Europe Colorectal Cancer Screening Market Size (2024 - 2029)

The Europe colorectal cancer screening market is projected to experience growth, driven by the implementation of strategies to address disruptions caused by the COVID-19 pandemic. These strategies include the use of stool-based tests, telehealth expansion, and personalized screening protocols. The increasing prevalence of colorectal cancer and the demand for advanced screening technologies further contribute to the market's expansion. Despite the high costs associated with screenings posing a challenge, the focus on product development and innovation by key players is expected to support market growth during the forecast period.

Home Market Analysis Healthcare Research Medical Devices Research Diagnostic Devices Research Clinical Diagnostic Devices Research Clinical Diagnostic Laboratory Equipment Research Disease Specific Diagnostic Devices Research Oncology Diagnostics Research Europe Cervical Cancer Screening Market Market Size

Market Size of Europe Colorectal Cancer Screening Industry

Europe Colorectal Cancer Screening Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Historical Data Period 2019 - 2022
CAGR 4.20 %
Market Concentration Low

Major Players

Europe Colorectal Cancer Screening Market Major Players

*Disclaimer: Major Players sorted in no particular order

Europe Colorectal Cancer Screening Market Analysis

The Europe colorectal cancer screening market is expected to grow at a CAGR of 4.2% during the forecast period.

  1. The COVID-19 pandemic affected healthcare systems in Europe. It also resulted in the interruption of usual care in many healthcare facilities. The pandemic posed several difficulties for the oncology community, particularly in diagnosing and treating cancer patients while guaranteeing both patient and professional immunity to the virus. A reduction in hospital visits, the discontinuation of the screening programs, and challenges with managing and operating cancer registries were major factors that were affected during the pandemic. 
  2. However, governments across countries in Europe took initiatives to overcome the losses incurred by the pandemic. According to an article published in April 2021 in World Journal of Gastrointestinal Oncology (WJGO), to overcome COVID-19-related disruption, strategies were applied, which included utilizing stool-based cancer tests, developing screening protocols based on individual risk factors, expanding telehealth, and increasing open access colonoscopies. 
  3. As per the source mentioned above, in Europe, a positive fecal immunochemical test (FIT) was recommended, followed up by a colonoscopy. Likewise, strategies and initiatives were adopted across European countries to manage colorectal cancer screening. Thus, these strategies and initiatives during and post-pandemic period in Europe impacted the market significantly. Hence, the market for colorectal screening is witnessing growth over the post-pandemic phase in Europe.
  4. The advent of efficacious genetic tests, the growing prevalence of colorectal cancer, and increasing cancer prevention initiatives are the primary factors that contribute to market growth.
  5. Colorectal cancer (CRC) comprises cancer of the colon and rectum. This is one of the most diagnosed forms of cancer and is responsible for severe mortality incidences. According to a press release by DiCE in June 2022, CRC is the 3rd most diagnosed cancer in men and the 2nd in women in Europe, with considerable variability among the 27 countries of the European Union. This shows that CRC creates a high burden on healthcare in Europe. Thus, the burden of CRC establishes a need for cancer screening for better diagnosis and treatment. This is expected to fuel the market growth over the forecast period.
  6. Additionally to a press release by the EC in March 2022, most European countries conduct screening for colorectal cancer. However, these existing services must be improved and updated to detect more colorectal cancer. This further creates demand for the availability of advanced and innovative devices, new cancer screening strategies, and initiatives, fuelling the market growth.
  7. Moreover, major players focus more on product development and innovation for CRC screening in the region. For instance, in November 2021, Fujifilm launched ColoAssist PRO, a real-time endoscope visualization system designed to assist endoscopists in performing colonoscopies. ColoAssist PRO is the latest system of Fujifilm's ELUXEO Ultra family of technologies. These innovations in technology and products are anticipated to fuel market growth over the forecast period.
  8. Therefore, due to the above-mentioned factors, the studied market is expected to grow significantly during the study period. However, the high costs associated with screenings are expected to restrain the market growth.

Europe Colorectal Cancer Screening Industry Segmentation

As per the scope of the report, colorectal cancer (CRC) is known as bowel and colon cancer. CRC screening tests use kits and various medical devices for diagnosing cancer. 

The Europe colorectal cancer screening market is segmented by screening tests (stool-based tests, colonoscopy, CT colonography (virtual colonoscopy), flexible sigmoidoscopy and other tests), and end-user (hospitals and diagnostic centers), and geography (Germany, United Kingdom, France, Italy, Spain and Rest of Europe). 

The report offers the value (in USD million) for the above segments.

Screening Tests
Stool-based Tests
Fecal Immunochemical Test (FIT)
Guaiac-based Fecal Occult Blood Test (gFOBT)
Stool DNA Test
Colonoscopy
CT Colonography (Virtual Colonoscopy)
Flexible Sigmoidoscopy
Other Tests
By End User
Hospitals
Diagnostic Centers
Geography
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Need A Different Region Or Segment?
Customize Now

Europe Colorectal Cancer Screening Market Size Summary

The Europe colorectal cancer screening market is poised for growth, driven by the increasing prevalence of colorectal cancer and the adoption of advanced screening technologies. The market is recovering from the disruptions caused by the COVID-19 pandemic, which had significantly impacted healthcare systems and cancer screening programs across the region. Governments and healthcare organizations have implemented strategies such as stool-based tests, telehealth expansions, and risk-based screening protocols to mitigate the pandemic's effects. These initiatives, coupled with the introduction of innovative genetic tests and cancer prevention programs, are expected to bolster market expansion. The demand for advanced screening devices and improved cancer detection strategies further fuels the market, as European countries strive to enhance their colorectal cancer screening services.

Colonoscopy remains a key focus within the market, recognized as the gold standard for colorectal cancer screening due to its effectiveness in detecting and removing precancerous lesions. The awareness and acceptance of colonoscopy procedures are increasing, supported by initiatives aimed at improving European colonoscopy standards. The United Kingdom is a significant contributor to market growth, with robust screening programs and government initiatives aimed at early cancer detection. The competitive landscape of the market is characterized by the presence of major players who are actively engaged in product development and strategic partnerships to enhance their market position. Overall, the Europe colorectal cancer screening market is expected to experience significant growth, driven by technological advancements, increased awareness, and supportive government policies.

Explore More

Europe Colorectal Cancer Screening Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Advent of Efficacious Genetic Tests

      2. 1.2.2 Growing Prevalence of Colorectal Cancer

      3. 1.2.3 Increasing Cancer Prevention Initiatives

    3. 1.3 Market Restraints

      1. 1.3.1 High Cost of the Screeing Tests

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 2.1 Screening Tests

      1. 2.1.1 Stool-based Tests

        1. 2.1.1.1 Fecal Immunochemical Test (FIT)

        2. 2.1.1.2 Guaiac-based Fecal Occult Blood Test (gFOBT)

        3. 2.1.1.3 Stool DNA Test

      2. 2.1.2 Colonoscopy

      3. 2.1.3 CT Colonography (Virtual Colonoscopy)

      4. 2.1.4 Flexible Sigmoidoscopy

      5. 2.1.5 Other Tests

    2. 2.2 By End User

      1. 2.2.1 Hospitals

      2. 2.2.2 Diagnostic Centers

    3. 2.3 Geography

      1. 2.3.1 Germany

      2. 2.3.2 United Kingdom

      3. 2.3.3 France

      4. 2.3.4 Italy

      5. 2.3.5 Spain

      6. 2.3.6 Rest of Europe

Europe Colorectal Cancer Screening Market Size FAQs

The Europe Colorectal Cancer Screening Market is projected to register a CAGR of 4.20% during the forecast period (2024-2029)

Abbott Laboratories, Epigenomics Inc., Exact Sciences Corporation, F. Hoffmann-La Roche AG and Novigenix SA are the major companies operating in the Europe Colorectal Cancer Screening Market.

Europe Colonoscopy Market Report Snapshots

Europe Colorectal Cancer Screening Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)